Related Experiment Videos
Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon
D Vallisa1, L Cavanna, R Berté
1Divisione Medica, Servizio di Ematologia, Ospedale Civile, Piacenza, Italia.
Acta Haematologica
|January 1, 1995
Summary
Interferon-alpha (IFN-alpha) therapy for hematologic malignancies rarely causes autoimmune issues. This study found few autoantibodies and no thyroid dysfunction in patients, suggesting a low incidence of these side effects.
Area of Science:
- Immunology
- Hematology
- Endocrinology
Background:
- Alpha-interferon (IFN-alpha) is widely used but associated with autoimmune side effects, particularly thyroid dysfunction.
- Existing data on IFN-alpha's autoimmune effects in hematologic malignancies are limited.
- This study investigates autoimmune disturbances and thyroid function in patients with hematologic malignancies receiving IFN-alpha.
Purpose of the Study:
- To determine the incidence of autoimmune-related disturbances and thyroid dysfunction in patients with hematologic malignancies treated with recombinant human IFN-alpha.
- To assess potential risk factors, such as sex, for developing autoimmune side effects during IFN-alpha therapy.
Main Methods:
- A cohort of 54 consecutive patients with hematologic malignancies treated with recombinant human IFN-alpha was studied.
- Patients were monitored for autoimmune-related disturbances and thyroid dysfunctions during a mean treatment duration of 15.9 months.
- Incidence of autoantibodies (antithyroglobulin, antinuclear) and clinical symptoms were recorded.
Main Results:
- Autoimmune disturbances were infrequent, with autoantibodies appearing in only 3 female patients (5%).
- Two patients developed antithyroglobulin antibodies without symptoms; one developed antinuclear antibodies with arthralgia and myalgia, leading to therapy interruption.
- No patient developed clinical thyroid dysfunction. Treatment dosage and duration did not correlate with autoantibody development, but female sex was a risk factor.
Conclusions:
- IFN-alpha therapy appears to have a low incidence of autoimmune side effects, including thyroid dysfunction, in patients with hematologic malignancies.
- Female sex is identified as a potential risk factor for developing autoantibodies during IFN-alpha treatment.
- Further research may be warranted to fully elucidate the long-term autoimmune risks in this patient population.